GlaxoSmithKline To Divest One Third Of Aspen Pharmacare Ltd. Stake For $740 Million

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - GlaxoSmithKline said on Tuesday it planned to reduce its investment in South African drugmaker Aspen Pharmacare by one third, although it would retain a board seat and a significant shareholding.

The sale of up to 28.2 million shares could realize some 7.54 billion rand ($741 million), based on current market prices.

Help employers find you! Check out all the jobs and post your resume.

Back to news